PE Anti-Human CD20 Antibody
英诺赛图(InnoCyto)的 PE Anti-Human CD20 Antibody(克隆 020AR1) 为大鼠源 IgG1 单克隆抗体,靶向 CD20(别名 MS4A-1),PE 标记(488 nm 蓝色激光激发),适用于流式细胞术。提供 25 tests、100 tests 规格,目录价 ¥814 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 PE Anti-Human CD20 Antibody(克隆 020AR1) 为大鼠源 IgG1 单克隆抗体,靶向 CD20(别名 MS4A-1),PE 标记(488 nm 蓝色激光激发),适用于流式细胞术。提供 25 tests、100 tests 规格,目录价 ¥814 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
101311 | 25 tests | ¥881
101312 | 100 tests | ¥2,034
105603 | 25 tests | ¥814
105604 | 100 tests | ¥1,492
Product Details
Regulatory Status|RUO
Protein Concentration|Supplied at a lot-specific concentration.
Storage&Handling|The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended Usage|For flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. PE has an excitation max at 565 nm and an emission max at 575 nm.
See All Formats|Clone 020AR1
Background Information
CD20 is a B cell-specific surface molecule that plays a key role in B cell activation and regulation and is best known as one of the most successful therapeutic targets in immunology and oncology. It is expressed on B cells from the late pre-B cell stage through mature and memory B cells but is absent on early pro-B cells and terminally differentiated plasma cells. This expression pattern makes CD20 an ideal marker for identifying and targeting the majority of circulating and tissue-resident B cells.
Structurally, CD20 is a small, non-glycosylated integral membrane protein with four transmembrane helices, two extracellular loops, and intracellular N- and C-terminal domains. Unlike many CD molecules, CD20 does not belong to the immunoglobulin superfamily and lacks a long cytoplasmic signaling motif. Instead, CD20 is thought to function as part of a membrane complex involved in ion transport, particularly calcium flux, which is critical for B cell activation and proliferation. Functionally, CD20 contributes to the regulation of B cell receptor (BCR) signaling by influencing calcium entry following antigen engagement. Through modulation of intracellular calcium levels, CD20 affects B cell activation, cell cycle progression, and differentiation. While CD20 is not essential for B cell development, it plays an important role in optimizing B cell responses during immune activation. A notable feature of CD20 is that it does not have a clearly defined natural ligand. Its activity appears to be mediated through homotypic interactions, association with other membrane proteins, and organization within lipid rafts rather than classical ligand–receptor binding. This lack of ligand has not limited its therapeutic utility, as CD20 is stably expressed and poorly internalized, properties that are advantageous for antibody-based targeting.
CD20 is implicated in a range of diseases characterized by pathological B cell activity. It is highly expressed on most B cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, making it a valuable diagnostic marker. In autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, autoreactive CD20⁺ B cells contribute to disease progression through autoantibody production and antigen presentation.
Therapeutically, CD20 has revolutionized the treatment of B cell-mediated diseases. Monoclonal antibodies targeting CD20 deplete B cells through mechanisms including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis. CD20-targeted therapies are widely used in hematologic malignancies and autoimmune disorders and have established B cell depletion as a powerful and durable therapeutic strategy.
Data Sheets
Human peripheral blood lymphocytes were stained with PE anti-Human CD20 clone 020AR1 (color filledhistogram) oranisotype control (gray histogram).
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). PE Anti-Human CD20 Antibody(101311)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/pe-anti-human-cd20-antibody.html.
TeleVM. (2026, November 12). PE Anti-Human CD20 Antibody(101311). 产品目录. https://www.suprotek.cn/products/item/pe-anti-human-cd20-antibody.html
@misc{biocsp_item_pe_anti_human_cd20_antibody,
title = {PE Anti-Human CD20 Antibody(101311)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/pe-anti-human-cd20-antibody.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源